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Abstract 
Background: Information regarding incidence of drug-drug interactions (DDIs) and adverse drug events 
(ADEs) among paediatric patients in Nigeria is limited. Methods: Prospective clinical audit among 
paediatric outpatients in four general hospitals in Nigeria over a 3-month period. ADEs documented in 
case files extracted.  Results: Among 1233 eligible patients, 208 (16.9%) received prescriptions with at 
least one potential DDI. Seven drug classes were implicated with antimalarial combination therapies 
predominating. Exposure mostly to a single potential DDI, commonly involved promethazine, 
artemether/lumefantrine, ciprofloxacin and artemether/lumefantrine. Exposure mostly to major and 
serious, and moderate and clinically significant, potential DDIs. Overall exposure similar across  all age 
groups and across genders. A significant association between severity of potential DDIs and age. Only 48 
(23.1%) of patients presented at follow-up clinics with only 15 reporting ADEs. Conclusion: There was 
exposure to potential DDIs in this population. However, potential DDIs were associated with only a few 
reported ADEs.  
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1. Introduction 
 
The intent of a prescribing doctor is to prescribe a medicine that is beneficial to the patients they treat, 
cure their disease or, at least, try and treat their symptoms, without causing harm. 1 However, poor 
knowledge of pharmacology of the medicines prescribed and prescribing errors can undermine this. 2 
Safe prescribing is a decision-making process whereby potentially hazardous drug-drug interactions 
(DDIs) and drug-disease interactions (contraindications) are avoided where possible. 3 
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Theoretically, DDIs are defined as a phenomenon of two or more drugs interacting in such a manner that 
the effectiveness or toxicity of one or more drugs is altered. 4 Drug interactions can occur at the level of 
many physiological processes in the body and can result in an increased effect of the interacting drugs 
(potential cause of an adverse drug event), or a decreased effect (potential loss of efficacy). 1 Interactions 
during drug absorption, distribution, hepatic metabolism, or renal excretion, resulting in an increased or a 
decreased plasma concentration that consequently alters the pharmacological effects, are termed 
pharmacokinetic interactions; while synergistic or antagonistic effects of two or more co-administered 
drugs, occurring at their sites of action, are termed pharmacodynamic interactions. 1, 5 Pharmaceutical 
interactions, otherwise called drug incompatibilities, can also occur when two or more drugs are mixed in 
the same device before administration, and are evidenced by reduced or interrupted activity of one or 
both drugs or formation of a new compound. 5  
 
The theoretical definition of drug interactions was based on the known pharmacological properties of the 
administered drugs, but in practice clinically relevant adverse events may rarely occur. The term potential 
DDIs are frequently used in clinical practice and refers to the prescription of potentially hazardous or 
contraindicated drug combinations. 1, 3 This phenomenon encompasses not only potential DDIs, but also 
some drug- disease interactions that are identified by drug combinations in which one of the drugs is 
contraindicated in a patient with a particular disease condition. 3 Thus, potential DDIs may far outnumber 
actual drug interactions in clinical practice. 1 
 
Patient harms from drug interactions are common and include adverse drug events (ADEs), prolonged 
hospitalization, increased treatment costs, morbidity and mortality. 1, 6 Average treatment costs for a 
single ADR in Germany have been estimated at approximatel\¼7 The costs of emergency related 
admissions due to ADRs have been estimated at GB£2billion annually in the UK8, with the cost of drug-
related morbidity and mortality exceeding US$177.4billion in the United States in 20009. Among 520 adult 
medical patients, Fokter and his colleagues observed potential DDIs in the prescriptions for 51% of 
patients on admission and 63% on discharge, of which 13% and 18%, respectively were identified as 
major. 10 Among a population of hospitalized pediatric patients in Brazil, potential DDIs were observed in 
61% of prescriptions, resulting in 1.9 interactions per prescription and approximately seven interactions 
per patient. Of these potential DDIs, 24% were clinically significant and ranged from severe (8%) and 
moderate (48.9%) to mild (3.2%). 11 A study conducted among elderly hypertensive patients in South-
west Nigeria also identified at least one potential DDI in 47.6% of the patients. 12  
 
Pediatric patients are at a high risk of adverse drug interactions as they handle drugs differently from 
adults. For example, the concentration of metabolizing enzymes and maturation of the organ-system for 
drug disposition differ in children and adults, resulting in altered drug disposition in children. 13 The 
concomitant and extensive utilization of more than two drugs for children is common in Nigeria 14, 
potentially enhanced by a greater prevalence of HIV and malaria among the population in Nigeria versus 
for instance Western countries. 15 Overall, a quarter of the malaria burden in Africa is found in Nigeria. 16, 
17 Polypharmacy has been identified as a risk factor for potential DDIs in adults.18, 19 As the policies 
guiding drug development and clinical trial studies in children have been reviewed 20, 21, the number of 
drugs, as well as multiple drug therapies, for children is likely to increase. As a result, the frequency of 
potential DDIs is likely to increase, which may be accompanied by a proportionate increase in major 
DDIs.   
 
Although it may be impossible to recognise every potential DDI in clinical practice, electronic prescribing 
systems software programmes have been introduced  to prevent adverse drug interactions through 
identifying potential DDIs in many developed countries.22-25 For example, SFINX (a drug-drug interaction 
database) was designed and integrated into clinical decision support systems in Sweden and Findland.23 
SFINX has also been used in website solutions for clinical evaluation of drug interactions.23 In 2009, over 
31,000 physicians and pharmacists received interaction alerts through SFINX and feedback from the 
users is continuously collected for regular improvement of the content of the database. 23 In the United 
States, Tatonetti et al. developed two novel signal detection algorithms and used them to generate 
databases for identifying off-target effects of individual drugs as well as drug-drug interactions. 24,25 While 
one algorithm uses machine learning techniques to identify common secondary effects and infer adverse 
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events without explicit reporting24, the other uses automated cohort matching to correct for biases 
inherent in large adverse events databases.25 Overall, the software package allows more robust and 
accurate drug safety surveillance. Furthermore, the databases for drug effects also serve as a resource to 
understand the pharmacology of small molecules needed for new drug development; an important 
concept in drug discovery and design.Such systems and resources, however, are currently lacking in 
developing countries. During the drug discovery processes, various algorithms and computational 
methods have been developed to predict drug interaction with nuclear receptors and enzymes catalysing 
most chemical reactions in cells.26, 27 The prediction tools are available to the public via a user-friendly 
server, enabling those working in a similar field to obtain data on drug-cell interactions. 27,28 It is hoped 
that development of such predicting tools for drug-drug interactions in clinical practice, and their 
availablity to the public domain, can help minimise the prescribing of potentially interacting drugs, 
especially in the developing countries. These, however, will be developments for the future. 
 
Currently  available literature on potential DDIs are typically based on studies performed in developed 
countries and among adult populations.3, 7 Drug interactions have not been explored among pediatric 
population, particularly in developing countries where drug utilization for children is high. 14 The few 
studies evaluating potential DDI in pediatric populations have been focused on inpatients, retrospective in 
nature and rarely identified the potential adverse events that may be associated with the interactions. 6, 29-
32 We aimed to rectify this by investigating the frequency of potential DDIs in the medications prescribed 
for pediatric outpatients attending hospitals in Nigeria. Potential adverse events associated with potential 
DDIs were also documented to provide future guidance to prescribers in Nigeria as well as wider African 
and other developing countries with similar populations. We believe this is the first study of its kind 
undertaken in Nigeria.  
 
2. Methods 
 
2.1 Study design 
We prospectively analyzed the clinical records of children who presented consecutively to the pediatric 
outpatient clinics at four General Hospitals (Mushin, Gbagada, Isolo and Surulere) in Lagos, Nigeria, 
between April 1 and June 30, 2015. These hospitals were chosen for the study since they are all situated 
in densely populated Local Government Areas and are likely to experience a very high patient load during 
clinic days. Outpatient clinics are held at each of the hospitals every Monday through Friday, between 8 
am and 4 pm. Lagos was chosen as this is the former capital of Nigeria and the most populous city .33 It 
should, therefore, provide a reflection of potential prescribing habits across Nigeria.   
 
The pediatric outpatient clinic in each of the hospitals is run by between 3-5 medical officers. On average, 
about 30 patients are seen each day at each of the outpatient clinics in the hospitals. All outpatient 
children who met the inclusion criteria were included in this study. These included children younger than 
18 years old that do not require hospital admission. Patients must have completely documented 
demographic information and prescribed medicines in the case files to be enrolled. We excluded 
neonates since they attend special baby clinics, which differ from the pediatric outpatient clinic. Patients 
prescribed topical preparations for application to the skin such as emollient, lotion, cream, or ointments; 
ear, eye and nasal drops; patches; inhalers; or on multivitamins and herbal supplements only were 
excluded since these are rarely evaluated in drug-drug interaction studies. If any of these drugs were 
prescribed along with other enteral and parenteral drugs, they were excluded from the list of drugs 
evaluated for potential interactions since the potential interactions associated with them are rarely 
documented in the databases to check. 
 
During the study, adolescents and parents or caregivers of young children were required to come for 
follow-up every week for 6 weeks and to take note of any untoward events that may occur while their 
child/ward took the prescribed medicines at home. In this study, children were classified into infants (1- 12 
months old), young children (1- 6 years old), children (6- 12 years old) and adolescents (12- 17 years old) 
according to the methods of Knoppert et al.  34 The attending physicians informed adolescent patients and 
caregivers of young children about the likely adverse effects of each drug prescribed according to their 
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documentation in the British National Formulary (BNF) for Children. 35 Such adverse events were reported 
at the clinic during follow-up and documented in the case file of the patients.  
 
2.2 Data abstraction 
Eligible cases were identified prospectively through the main register obtained from the medical record of 
each outpatient clinic after 4 pm throughout the study period. These are case files returned from the 
pediatric outpatient clinic each day to the medical record office. Four registered nurses, trained for this 
research, one per study center, reviewed each case file on a daily basis, and - using a standardized form 
purposively designed for the study - extracted data on age and gender of the patient, prescribed 
medicines and their route of administration.  
 
2.3 Identification of potential interactions between paired co-prescribed drugs 
The co-prescribed drugs were screened in pairs for potential interactions using reference books9, 35 as 
well as online references such as Medscape Reference Drug Interaction Checker36. This electronic 
resource had been validated in our previous study where clinically-significant drug interactions in HIV-
infected children were profiled. 37 The potential DDIs not identified by the two reference books or those 
with the severity rated as contraindicated (category X) or unknown (category A) by the online database 
were searched from a second database - drugs.com. 38 This was to ensure that important DDIs were not 
missed out of the total potential DDIs. The lack of access to other electronic resources for potential DDI 
checks in our environment restricted us to use the reference books and the two freely available online 
resources.  
 
2.4 Classification of potential interactions between paired co-prescribed drugs 
The severity and category of potential DDIs were based on the classifications used in our previous study. 
39 The details of the severity rating scale (A to D and X) are presented in Table 1.  
 
Insert Table 1 
 
We excluded from our analysis the drug pairs that yielded no or unknown interactions (A rating). If a given 
drug interaction was listed more than once with different risk ratings, the most severe risk rating was used 
to determine the severity grade. The mechanism of action of the interactions, and their management, 
were as documented in the interaction checkers. Evidence for documentation of the potential DDI in the 
literature is classified according to the method of Feinstein et al. as excellent (existence of the drug 
interaction is clearly established by randomized controlled trial studies), good (reports in the literature 
strongly suggests that the interaction exists, but not supported by well-controlled studies), fair (the 
interaction is scarcely documented in the literature; however, the interaction is suspected based on some 
pharmacologic considerations of the interacting drugs), poor (only few studies and limited reported cases 
support the existence of the interaction), or unlikely (insufficient documentation  of the interaction in the 
literature and no pharmacological basis). 29  
 
2.5 Identification of potential adverse events associated with the interactions  
Only adverse events associated with contraindicated, major and moderate interactions reported in the 
interaction checkers are listed in this study. Since minor interactions typically have no clinical significance, 
no adverse event is attributed.  Patients or their caregivers were advised to report immediately any 
observed adverse event. They were also interviewed by the attending physicians for suspected adverse 
events during their weekly follow-up visits. The nurses reviewed the case file of each patient prospectively 
during follow-up visit, weekly for six weeks to specifically look for documentation of any potential adverse 
event known to be associated with the interactions that was documented by the attending physicians.  We 
classified adverse events that are related to the drug-drug interactions according to the Medscape 
interaction checker. 36 Patients who experienced moderate to severe ADEs were admitted and treated as 
such, while those who experienced mild ADEs were observed closely. 
 
2.6 Statistical Analysis 
The demography of the patients and pattern of medicines prescribed in the study cohort are described by 
frequencies and percentages. To describe the prevalence of potential DDIs, the frequencies and 
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percentages of specific potential DDIs were calculated per patient. We then determined the exposure per 
patient exposed as the ratio of percentage potential DDI exposure to the percentage of patients exposed. 
 
The potential DDI patterns are also described according to the age group of the patients. For each 
potential DDI, we determined the frequencies and percentages of the implicated drug pairs, the severity 
of the interaction, and the level of scientific evidence for the interaction. Finally, we also determined the 
frequency and percentage of all potential DDIs associated with each of the different categories of 
potential ADEs. Each potential DDI could be associated with one or more potential ADE. 
 
Statistical analyses were performed with SPSS version 17. The association between severity of the 
potential DDI and age group of the patients or gender was determined with Yates' chi-square test (if any 
expected frequency is below 1 or if the expected frequency is less than 5 in more than 20% of the cells), 
otherwise a Pearson Chi-square test was used, at a significant p-value of <0.05.  
 
3. Results 
 
Over the three-month study period, 2535 patients were seen at the pediatric outpatient clinics. At least 
one prescription was received by 2000 (78.9%) patients but only 1233 (61.6%) patients who met the 
inclusion criteria were included and analyzed in this study. More males (705; 57.2 %) than females (528; 
42.8%) were recorded in this study. Their mean age was 3.73 ± 0.16 years.   
 
3.1 Pattern of drugs prescribed 
Of the eligible patients, 208 (16.9%) received prescriptions with at least one potential DDI. These patients 
were prescribed a total of 480 drugs with potential for interactions. Table 2 shows the classes of drugs 
implicated for potential DDI in this study.  
 
Insert Table 2 
 
Among the seven classes of drugs implicated, antimalarials, predominantly the Artemisinin-based 
Combination Therapies (ACTs), were the most implicated (179; 37.3%), followed by 
antiemetics/antihistamines (126; 26.3%), and antimicrobials (103; 21.5%). The ACTs 
(artemether/lumenfantrine and artemether/amodiaquine) (179; 37.3%) and promethazine (118; 24.6%) 
were the two specific drugs most commonly implicated in the potential DDIs.  
 
3.2 Profile of the drug-drug interactions 
Altogether, 240 potential DDIs were identified; majority of which were a single DDI (188; 78.3%). Ten 
patients were exposed to three potential DDIs (30; 12.5%), nine were exposed to two potential DDIs (18; 
7.5%) and only one patient was exposed to four potential DDIs. 
 
The co-prescribed drug pairs with potential for interaction, to which the patients were exposed, as well as 
the profile of the interactions are presented in Table 3.  
 
Insert Table 3 
 
The patients were most exposed to promethazine and artemether/lumefantrine (111; 46.2%) and 
ciprofloxacin and artemether/lumefantrine (39; 16.2%) drug pairs with potential for interactions. The most 
identified potential DDI, based on the severity, was major and serious (141; 58.8%), followed by moderate 
and clinically significant (83; 34.5%), minor (12; 5.0%) and contraindicated (4; 1.7%) types (Table 3). 
Excellent (33; 13.8%) and good (9; 3.8%) scientific evidence for the potential DDIs were documented in 
the literature (Table 3).  
 
Furthermore, the severity of the potential DDI was compared with the age and gender of the patients in 
Table 4.  
 
Insert Table 4 
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The overall exposure to potential DDIs was highest among infants (106; 44.1%) and higher for male 
patients (138; 57.5%). There was a significant association between the severity of potential DDIs and 
SDWLHQWV¶DJHVS EXWQRWZLWKWKHLUJHQGHUS  However, there was a slight differenece in 
the exposure per exposed patients across all age groups and  across both genders.   
The exposure per exposed patient ratio differs slightly among all the interacting drug pairs prescribed to 
patients (Table 5). The possible adverse events that may result from the potential DDIs and how these 
interactions can be prevented are presented in Table 5.  
 
Insert Table 5 
 
Of the 208 patients who received prescriptions for drugs with potential for interactions, only a few (48; 
23.1%) presented to the follow-up clinic over the six ZHHNV¶ period. Among the 48 patients seen at the 
follow-up clinic, 15 reported ADEs of which 8 (53%) were to promethazine and artemether/lumefantrine 
(fainting spells-3, dizziness- 3, and palpitations-2), 4 (27%) to promethazine and metoclopramide (tongue 
protrusion- 1, lip smacking-1, restlessness- 1, and abnormal movement of the neck-1), and 3 (20%) to 
ciprofloxacin and artemether/lumefantrine (fainting spell-1, dizziness- 1 and palpitation-1) (Figure 1). 
None of the ADEs required medical intervention since they lasted for less than 24 hours. Furthermore, 
none of the patients presented to the emergency room because of the ADEs.  
 
Insert Figure 1 
 
4. Discussion 
 
Among the cohort of pediatric outpatients treated in Nigeria, less than a quarter (16.9%) were exposed to 
at least one potential DDI.  Studies evaluating drug-drug interactions in pediatric population are few and 
focused on inpatients. 6, 29-32 Among DODUJHFRKRUWRISHGLDWULFSDWLHQWVWUHDWHGDWFKLOGUHQ¶VKRVSLWDOVLQ
the United States, Feinstein et al reported a much higher exposure (49%) of the patients to potential DDI 
during their admission. 29 Higher exposures than observed in our study were reported among hospitalized 
children in Yugoslavia (24.6%) and Pakistan (25.8%).  31, 32 However, a very low exposure (3.83%) was 
reported among hospitalized children in Czech Republic. 30 Variation in the disease pattern necessitating 
the varied prescription pattern, age groups of the children included in the studies, settings of the studies, 
samples sizes, and duration of the studies may have resulted in the differences in the potential DDIs 
reported in all the studies.  
 
Our study, like the American study, excluded neonates while this class of children was involved in other 
studies. We also only evaluated outpatient prescriptions while other studies evaluated prescriptions for 
hospitalized children. The sample sizes for all, but the American study, was small and varied from ours. In 
addition, we identified potential DDIs from the BNF for Children6WRFNOH\¶V'UXJ,QWHUDFWLRQUHIHUHQFH
book, free online Medscape interaction  and drugs.com databases, while Micromedex Drug-Reax® or 
INFOPHARM Drug Interactions Compendium® Software were widely used in other studies4, 27,29, 32 
However, the Yugoslavian study did not document the assessment tool for identifying potential DDIs.31 
The lack of a standardized assessment tool for potential DDI studies may also have contributed to the 
varied potential DDI exposures in the different studies. Previous studies have reported discrepancies in 
potential DDI listings in various databases for drug interaction checks. 37, 61 
 
Artemisinin-based Combination Therapy (ACT) for malaria predominates (37%) the list of drugs 
responsible for the potential DDIs in our study, which underscores the burden of malaria in pediatric 
outpatients in Nigeria. By contrast, opioids (25%) were the drugs most involved in potential DDIs in 
hospitalized children in the United States.29 This further highlights the effects of disease and prescription 
patterns on exposure of children to potential DDI.   Many of the antimalarial and antiemetic drugs, which 
were implicated in most of the potential DDIs, were prescribed for intramuscular administration. Other 
medicines, including amikacin, gentamicin, and some of the analgesics, were also prescribed for 
intramuscular administration.  This is contrary to all guidelines, including the standard treatment guideline 
in Nigeria, for routine pediatric outpatient treatment where the practice was discouraged because of 
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potential complications such as abscess and hematoma formation, infection transmission and allergic 
reactions.62  
 
Contraindicated (1.7%) as well as major and significant (58.8%) potential DDIs occurred in our patients.  
Varying results were, however, reported for contraindicated (5%) and major (41%) potential DDIs among 
hospitalized children in the United States. 29 Within the confines of our study, only a single drug pair 
(phenobarbital and artemether/amodiaquine) were implicated in the contraindicated potential DDI, whilst 
10 different drug pairs (ibuprofen and ketorolac, fluconazole and ondansetron, calcium chloride and 
ceftriaxone, aspirin and ketorolac, glycopyrrolate and potassium chloride, calcium gluconate and 
ceftriaxone, metoclopramide and promethazine, ketorolac and naproxen, epinephrine and linezolid, and 
atropine and potassium chloride) were implicated in the larger American cohort. 29 Potential explanations 
for the differences seen include diseases and health conditions necessitating hospitalization that are likely 
to be more severe than among outpatients. Consequently, more medicines may be utilized by pediatric 
inpatients versus outpatients.  
 
Among the interacting drug pairs in our study and others, some are avoidable by replacing one of the 
pairs with another medicine in the same pharmacological group based on the mechanism of drug 
interactions. However, some of the interacting drug pairs are unavoidable because of their high 
therapeutic benefit versus minor consequences of the interactions. Unfortunately, the likely drug 
substitution among the interacting pairs to avert the potentially avoidable interactions, without necessarily 
affecting disease treatment , has not been addressed. For those interacting drug pairs (promethazine and 
artemether/lumefantrine; ciprofloxacin and artemether/lumefantrine; and promethazine and 
metoclopramide) that resulted in reported adverse events, we believe chlorpheniramine, 
diphenhydramine, cetirizine, and metoclopramide are good substitutes for promethazine co-prescribed 
with artemether/lumenfantrine since these combinations would not produce adverse interactions.36,38 
Cefepime can be substituted for ciprfloxacin in combination with artemether/lumefantrine since they have 
a similar wide spectrum for bacterial infections.35,38 Both promethazine and metoclopramide are 
antihistamines with similar mechanism of action. It will be prudent to use just one from the same class or 
combine one with another from a different class and mechanism of action. Ondansetron could be 
substituted for either promethazine or metoclopramide since their combinations do not interact 
adversely.35,36,38 For contraindicated interacting pairs (phenobartital and artemether/amodiaquine), 
lorazepam could be substituted for phenobarbital since this new pair rarely interact adversely.36,38 
 
Increased drug prescription is an identified risk for potential DDI.  32 Based on the type of electronic 
database used for interaction checks in our study, metoclopramide and promethazine drug pair would 
result in major and serious interaction, while Micromedex Drug-Reax® rated the interaction as 
contraindicated. 29 We may have, therefore, underestimated the proportion of contraindicated interactions 
in our study or this may have been overestimated in a previous study. 29 This further underscores the 
significance of developing a uniform assessment tool for future drug interaction studies. Discrepancies in 
the rating of severity of potential DDIs by the information sources used in the present and previous 
studies may have also resulted in the variety of drug pairs implicated in the contraindicated interactions 
reported in the American study.   
 
Only a few potential DDIs have an excellent (13.6%) and good (3.8%) scientific evidence in the literature. 
Other studies have documented higher levels (60%-80%) of evidence for assignment of severity to a 
potential DDI as good to excellent. 29, 31, 32 This suggests that majority of the potential DDIs observed in 
our study may only occur in theory and may not be very significant clinically. Clinicians may tend not to 
prescribe many of the drug pairs responsible for the majority of the potential DDIs in this study, when 
indeed the interactions are clinically not significant. Such practice may cause an unnecessarily avoidance 
of useful therapy options for patients thereby denying them optimal treatments. It has been documented 
previously that many interactions rated moderate and clinically significant by Micromedex and Lexicomp 
databases were found to be clinically insignificant by doctors and pharmacists. 61 This needs to be borne 
in mind in the future.  
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The high prevalence of potential DDI exposures in our study could have resulted in a wide range of 
potential ADEs (Table 5).  This, however, did not correspond with the rates of actual ADEs reported by 
patients during their follow-up. This may have resulted from the low follow-up rates (23%) in our study. 
Alternatively, it could be possible that ADEs did occur but were unrecognized by the patients, their 
caregivers or the attending physicians. Recognizing ADEs from exposure to potential DDIs could be 
challenging to healthcare professionals and even more challenging to patients and their caregivers. 63, 64 
This will be followed-up in future studies along with other means of following up patients such as the use 
of mobile phone calls or home visits to potentially identify additional patients who may be experiencing 
adverse events, and this will be the subject of future studies to confirm or dispute our findings. 
 
There was a significant association between the age of the patients and the severity of the interaction 
exposures in this study. Infants and young children are more exposed to potential DDIs than older 
children and adolescents. By contrast, older children and adolescents were more exposed than young 
children to potential DDIs among hospitalized children in the United States 29 and Czech Republic. 31 
Ismail et al reported a significant association between potential DDI and female gender 32, while no 
significant association was observed in our study and among hospitalized children in Czech Republic. 30 
Variation in age group classification and settings of the studies, as well as methodological and sample 
size differences, may have accounted for the differences seen between the findings in ours versus other 
published studies.   
 
We acknowledge several limitations with our study. A major limitation is that we did not assess the doses 
of interacting drug pairs prescribed for patients. Since children are often prescribed medicines based on 
their body weight  or body surface area; overdosing of one of the interacting drug pairs can impact on 
potential adverse interactions. The potential interaction of drugs such as isoniazid with other co-
formulated drugs (pyrazimnamide, ethambutol and rifampicin) is dose dependent and results in adverse 
toxicity (peripheral neuropathy) when the administered dose exceeds  300 mg/day.65 At a recommended 
dose of 5mg/kg/day, prophylactic or therapeutic use of isoniazid rarely causes adverse toxicity.65  
Ciprofloxacin is known to increase the exposure of cyclosporine when both drugs are co-administered. 
This beneficial potential DDI, following timely dosage adjustment of cyclosporine, increases 
immunosuppresive serum levels in patients with bone marrow aplasia without experiencing any adverse 
toxicity.66 
 
Other limitations include conducting the study in only four general hospitals in Lagos, and only actively 
following up a minority of patients. We also accept our data was based only on the evaluation of 
prescriptions as we did not have direct information about those patients who actually used the prescribed 
medicines. Consequently, adherence to the medications prescribed cannot be ascertained among those 
who used the prescribed interacting drugs. In addition, in a country battling with an epidemic of 
adulterated, counterfeit and fake medicines 67, we accept it may also be necessary to directly measure the 
plasma levels of each drug exposure. Doing this would enable us to know the extent to which the 
medicines prescribed are involved in clinically significant interactions. Rational prescribing is based on the 
risk-benefit ratio of a medicine to patients. It is, however, believed that the benefits of co-prescribing 
potentially interacting drugs might have outweighed the risks for the condition being treated. Despite 
these limitations, we believe our findings are valid but may require further studies involving all six geo-
political zones before they could be generalized for Nigeria as a whole. We also accept future studies 
should consider including both public and private hospitals across the six geo-political zones in Nigeria. 
The use of electronic medical recording systems could also improve the quality of data generated in 
future studies. These are consdierations for the future building on our initial study. 
 
Finally, as shown in a series of recent publications demonstrating new approaches to predicting drug-cell, 
drug-disease, and drug-drug interactions, using user-friendly and publicly accessible web-servers 
23,27,28,68-72, as well as freely available online databases such as the Medscape  Reference Drug 
Interaction Checker36 used in our study, would significantly reduce adverse drug interactions in resource 
limited countries such as Nigeria. 
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5. Conclusions and recommendations 
 
Outpatient children are frequently exposed to potential DDIs in Nigeria and may be at risk of adverse drug 
events.  Continuing education of prescribers and regular use of freely available online information 
resources on potential drug interactions could be beneficial towards inproving rational prescribing and 
minimizing adverse drug interactions among this population in the future. However, tempered by the fact 
that these can highlight potential ADEs that are not clinically significant and result in sub-optimal 
treatment of patients. 
 
Overall, we recommend that clinicians are discouraged, through educational and other programs, to 
reduce the administration of intramuscular injections where oral formulations are just as effective. 
Clinicians should also be well grounded in the pathophysiology of pediatric diseases and the mechanism 
of action of the drug combinations prescribed, as well as the risk-benefit of the drugs, while monitoring for 
their potential adverse interactions. Collaboration between prescribers and pharmacists could further 
promote rational medicine use for children and reduce potential DDIs and any consequent ADEs.  Careful 
consideration of medicines contraindicated or without indications in specific age-groups, for instance the 
use of promethazine in children under the age of two years, and the use of a handbook of medicines for 
children are other potential means of promoting rational medicine for children that should be embraced by 
the prescribers in Nigeria.  This will be followed up. 
 
6. Five-year review 
 
We expect over the next five years that continuing education of prescribers, greater collaboration 
between prescribers and pharmacists, as well as greater availability of freely available online information 
sources, will further improve rational rescribing and mimimse potential drug-drug interactions. This will 
include greater recognition that some potential ADEs are not clinically significant; consequently, care 
should be taken in order not to result in sub-optimal treatment. 
 
There will also be continued educational and other programmes to reduce the use of intramusvular 
injections where oral formulations are just as effective. This will be helped by strengthening regulations 
regarding the supply of medicines in Nigeria including reducing the extent of self-purchasing of medicines 
through a variety of sources. 
 
7. Key Points 
 
x Pediatric patients are at a high risk of adverse drug interactions as they handle drugs differently from 
adults. However available literature on potential DDIs are typically based on studies performed in 
developed countries and among adult populations 
x Outpatient prescriptions among paediatric outpatients in Nigeria were associated with exposure to 
potential drug-drug interactions, which resulted in some adverse drug events 
x Antimalarial drug class, particularly the artemisinin combination therapies (ACTs), were the most 
implicated drugs in potential drug-drug interactions. This suggests that disease patterns, which 
dictate drug utilization pattern, play a pivotal role in exposure to drug-drug interactions 
x Potential drug-drug interactions due to prescription of contraindicated drugs were few; infants and 
young children being those at risk 
x The use of freely available online drug information resources on potential drug-drug interaction is 
feasible in developing countries, particularly Nigeria. Encouraging prescribers to use this tool could 
prevent avoidable and unnecessary exposures to potential drug-drug interaction in children 
x Interventions are required to avoid prescription of two or more similar drugs, such as promethazine 
and metoclopramide, with the potential for additive adverse events. Interventions are also needed to 
reduce the administration of intramuscular injections where oral formulations are just as effective 
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Tables 
Table 1: Drug±drug interaction rating scale 
 
Rating Category Action Explanation 
X Contraindicated Avoid 
combination 
The drugs are contraindicated for concurrent use 
D Major Consider 
therapy 
modification 
The interaction may be life threatening and/or require 
medical intervention to minimize or prevent serious 
adverse events 
C Moderate Monitor therapy 7KHLQWHUDFWLRQPD\UHVXOWLQH[DFHUEDWLRQRIWKHSDWLHQW¶V
condition and/or require an alteration in therapy 
B Minor No action 
needed 
The interaction would have limited clinical effects. May 
include an increase in the frequency or severity of side 
effects but generally would not require a major alteration in 
therapy 
A Unknown No known 
interaction 
Unknown 
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Table 2: The pattern of drugs with potential for interactions prescribed for patients attending 
general peadiatric outpatient clinics of four general hospitals in Lagos, Nigeria 
 
Drug class 
Frequency of prescription (%) 
Antimalarial  
    Artemether/lumenfantrine 171(35.6) 
    Artemether/amodiaquine 8(1.7) 
Antiemetic/antihistamine  
    Promethazine 118(24.6) 
    Metoclopramide 8(1.7) 
Antimicrobial  
     Ciprofloxacin 44(9.2) 
     Erythromycin 13(2.7) 
     Cotrimoxazole 12(2.5) 
     Azithromycin 11(2.3) 
     Amoxicillin 10(2.1) 
     Gentamicin 5(1.0) 
     Amikacin 4(0.8) 
     Metronidazole 4(0.8) 
Analgesic  
    Ibuprofen 13(2.7) 
    Paracetamol 9(1.9) 
    Diclofenac 9(1.9) 
Anticoagulants  
   Warfarin 28(5.3%) 
Anticonvulsant  
  Phenobarbital 4(0.8) 
Total 480(100.0) 
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Table 3: The pattern of interacting drug pairs and their profiles 
 
Interacting drug pairs Frequency of 
prescription (%) 
Severity 
 
 
 
Rating Documentation of 
evidence for 
Potential DDI in the 
literature 
Phenobarbital and artemether/amodiaquine 4(1.7) Contraindicated X Fair 36, 38 
Promethazine and artemether/lumefantrine 111(46.2) Major and serious D Fair 36, 38 
Erythromycin base and artemether/lumefantrine 13(5.4) Major and serious D Fair 40, 41 
Furosemide and gentamicin 5(2.1) Major and serious D Excellent 42, 43  
Furosemide and amikacin 4(1.7) Major and serious D Excellent 42, 43 
sulfamethoxazole (septrin) and warfarin 4(1.7) Major and serious D Good 44, 45 
Promethazine and metoclopramide 4(1.7) Major and serious D Fair 46 
Ciprofloxacin and artemether/lumefantrine 39(16.2) Moderate and clinically significant C Fair 36, 38 
Amoxicillin and warfarin 10(4.2) Moderate and clinically significant C Excellent 47-49 
Paracetamol (acetaminophen) and warfarin 9(3.7) Moderate and clinically significant C Excellent 50-53 
Azithromycin and artemether/lumefantrine 8(3.3) Moderate and clinically significant C Fair36, 38 
Ibuprofen and warfarin  5(2.1) Moderate and clinically significant C Excellent 54-57  
Diclofenac and ciprofloxacin 5(2.1) Moderate and clinically significant C Good 58-60 
Metronidazole and artemether/amodiaquine 4(1.7) Moderate and clinically significant C Fair 36, 38 
Promethazine and azithromycin 3(1.2) Moderate and clinically significant C Fair36, 38 
sulfamethoxazole (septrin) and ibuprofen 8(3.3) Minor B Fair36, 38 
Diclofenac and metronidazole  4(1.7) Minor B Fair36, 38 
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Table 4: Comparing the age and gender of the patients with the severity of potential drug-drug interaction exposures 
 
Characteristics Frequency      
(%) 
Severity and prevalence of potential drug-drug interaction (%) P- value Exposure/exposed 
ratio 
Contraindicated Major Moderate Minor Overall  
Age         
 Infants 87 (41.8) 2 (0.8) 73 (30.4) 29 (12.1) 2 (0.8) 106 (44.1) 0.046*¶ 1.06 
Young children 65 (31.3) 2 (0.8) 29 (12.1) 30 (12.5) 5 (2.1) 66 (27.5)  0.88 
Older Children 52 (25.0) 0 (0.0) 32 (13.3) 28 (11.7) 5 (2.1) 65 (27.1)  1.08 
Adolescent 4 (1.9) 0 (0.0) 3 (1.3) 0 (0.0) 0 (0.0) 3 (1.3)  0.68 
Gender  
Male 122 (58.6) 2 (0.8) 84 (35.0) 45 (20.8) 7 (2.9) 138 (57.5) 0.631¶ 0.98 
Female 86 (41.4) 2 (0.8) 53 (22.1) 42 (17.5) 5 (2.1) 102 (42.5)  1.03 
*significant p value, ¶Yates' chi-square test 
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Table 5: The mechanism of action of the interacting drug pairs, proportion of exposure to the event and the exposed children, 
associated adverse events and their management 
 
Interacting drug pairs Mechanism of action Overall 
exposure 
(%) 
Number of 
patient 
exposed 
(%) 
Exposure per 
exposed patient ratio 
(Percentage 
exposure/percentage 
exposed) 
Potential 
adverse event 
Management 
Promethazine and 
artemether/lumefantrine* 
 
Both increase QTc 
interval  
111(46.2) 96(46.2) 1.00 Sudden 
dizziness**, 
lightheadedness, 
fainting**, 
shortness of 
breath, or 
palpitations** 
Combination is 
strongly 
discouraged 
unless benefits 
outweigh risks 
or no 
alternatives 
available.  
Use alternative 
drugs to either 
of the drugs. 
Ciprofloxacin and 
artemether/lumefantrine* 
Both prolong QT interval 
and cause torsades de 
pointes (TdP). However, 
ciprofloxacin elicits 
minimal effects on QT 
interval  
39(16.2) 34(16.3) 0.99 Sudden 
dizziness**, 
lightheadedness, 
fainting**, 
shortness of 
breath, or 
palpitations** 
Monitor patient 
closely.  
 
Erythromycin base and 
artemether/lumefantrine 
Both prolong QTc interval 
and may result in serious 
or life-threatening 
interaction. 
Artemether/lumefantrine 
decreases the level or 
effect of erythromycin 
base by affecting hepatic 
and/or intestinal enzyme 
CYP3A4 metabolism.  
13(5.4) 13(6.2) 0.87 Sudden 
dizziness, 
lightheadedness, 
fainting, 
shortness of 
breath, or heart 
palpitations 
Combination is 
strongly 
discouraged 
unless benefits 
outweigh risks 
and no 
alternatives 
available. 
Use alternatives 
to either of the 
drugs 
Amoxicillin and warfarin Amoxicillin increases the 
effects of warfarin by 
10(4.2) 8(3.8) 1.11 Unusual 
bleeding or 
Monitor patient 
closely. 
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either interference with 
the CYP2C9-dependent 
liver metabolism of 
warfarin or alterations in 
normal gut flora resulting 
in reduced intestinal 
vitamin K synthesis. 
Amoxicillin may enhance 
anticoagulant effect of 
vitamin K antagonists 
bruising, 
swelling, 
vomiting, blood 
in the urine or 
stools, 
headache, 
dizziness, or 
weakness 
Paracetamol 
(acetaminophen) and 
warfarin 
Paracetamol increases 
the effects of warfarin by 
an unknown mechanism 
9(3.7) 5(2.4) 1.54 Unusual 
bleeding or 
bruising, 
swelling, 
vomiting, blood 
in the urine or 
stools, 
headache, 
dizziness, or 
weakness 
Monitor patient 
closely. 
Azithromycin and 
artemether/lumefantrine 
Both drugs increase QTc 
interval 
8(3.3) 5(2.4) 1.38 Sudden 
dizziness, 
lightheadedness, 
fainting, 
shortness of 
breath, or 
palpitations 
Monitor patient 
closely. 
sulfamethoxazole 
(septrin) and ibuprofen 
Sulfamethoxazole will 
increase the level or 
effect of ibuprofen by 
affecting hepatic enzyme 
CYP2C9/10 metabolism 
8(3.3) 5(2.4) 1.38  No action 
suggested. 
Ibuprofen and warfarin  High protein binding and 
the cytochrome P450 
(CYP)-dependent 
clearance mechanisms of 
NSAIDs can affect the 
5(2.1) 5(2.4) 0.88 Unusual 
bleeding or 
bruising, 
vomiting, blood 
in urine or 
Use with 
caution and 
monitor patient 
closely. 
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serum levels of warfarin stools, 
headache, 
dizziness, or 
weakness 
Diclofenac and 
ciprofloxacin 
Mechanism of the 
interaction is unknown 
but there is increased risk 
of CNS stimulation and 
seizures with high doses 
of fluoroquinolones 
5(2.1) 5(2.4) 0.88 Tremors, 
involuntary 
muscle 
movements, 
hallucinations, or 
seizures 
Use with 
caution and 
monitor patient 
closely 
Furosemide and 
gentamicin 
Either increases 
nephrotoxicity or 
ototoxicity of the other by 
pharmacodynamic 
synergism. 
 
5(2.1) 5(2.4) 0.88 Hearing loss, 
dizziness, 
numbness, skin 
tingling, muscle 
twitching, or 
seizures which 
may be signs of 
nerve damage 
Monitor patient 
very closely.  
Use alternatives 
to either of the 
drugs.  
Phenobarbital and 
artemether/amodiaquine 
Phenobarbital decreases 
the level or effect of 
artemether/amodiaquine 
by affecting 
hepatic/intestinal enzyme 
CYP3A4 metabolism 
4(1.7) 4(1.9) 0.89 Prolonged 
malaria 
symptoms 
Contraindicated 
and never use 
the 
combination. 
Use alternatives 
to either of the 
drugs 
Furosemide and 
amikacin 
Either increases 
nephrotoxicity or 
ototoxicity of the other by 
pharmacodynamics 
synergism.  
 
4(1.7) 4(1.9) 0.89 Hearing loss, 
dizziness, 
numbness, skin 
tingling, muscle 
twitching, or 
seizures which 
may be signs of 
nerve damage 
Monitor patient 
very closely.  
Use alternatives 
to either of the 
drugs. 
sulfamethoxazole 
(septrin) and warfarin 
Sulfamethoxazole 
increases effects of 
warfarin by decreasing 
metabolism. 
Sulfamethoxazole 
increases effects of 
4(1.7) 4(1.9) 0.89 Dizziness; 
lightheadedness; 
red or black, 
tarry stools; 
coughing up or 
vomiting fresh or 
Monitor patient 
very closely.  
Use alternatives 
to either of the 
drugs. 
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warfarin by plasma 
protein binding 
competition. 
Trimethoprim-
sulfamethoxazole 
interacts with racemic 
warfarin, possibly at a 
receptor-site locus. 
 
dried blood that 
looks like coffee 
grounds; severe 
headache; 
weakness; 
morbilliform 
rash; and 
generalized 
pruritus. 
Metronidazole and 
artemether/amodiaquine 
Metronidazole increases 
the level or effect of 
artemether/amodiaquine 
by affecting hepatic 
and/or intestinal enzyme 
CYP3A4 metabolism 
4(1.7) 4(1.9) 0.89 Sudden 
dizziness, 
lightheadedness, 
fainting, 
shortness of 
breath, or 
palpitations 
Monitor patient 
closely. 
Promethazine and 
metoclopramide* 
Both increase 
antidopaminergic effects, 
including extrapyramidal 
symptoms and 
neuroleptic malignant 
syndrome 
4(1.7) 4(1.9) 0.89 Abnormal 
muscle 
movements, 
especially of the 
face and limbs**. 
Other adverse 
events include 
lip smacking**, 
chewing, 
puckering, 
frowning or 
scowling, tongue 
thrusting**, teeth 
clenching, jaw 
twitching, 
blinking, eye 
rolling, shaking 
or jerking of 
arms and legs, 
tremor, 
jitteriness, 
restlessness**, 
pacing, and foot 
Monitor patient 
closely. 
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tapping. 
Diclofenac and 
metronidazole  
Metronidazole increases 
the level or effect of 
diclofenac by affecting 
hepatic enzyme 
CYP2C9/10 metabolism 
4(1.7) 4(1.9) 0.89  No action 
suggested. 
Promethazine and 
azithromycin 
Promethazine and 
azithromycin both prolong 
QTc interval 
3(1.2) 3(1.4) 0.86 Sudden 
dizziness, 
lightheadedness, 
fainting, 
shortness of 
breath, or 
palpitations 
Monitor patient 
closely. 
Note: *represents the drug pair that produced the adverse events reported by patients; ** represents the specific adverse events reported by the 
patients after exposure to the corresponding interacting drug pairs
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Figure 1. The 15 reported adverse events (ADEs) among 48 patients presenting at the follow-up clinic 
 
